1. Alto's Phase 2b trial for ALTO-100 failed to meet primary endpoints. 2. ANRO stock dropped nearly 70% following the announcement. 3. Analysts have reduced the price target for ANRO significantly. 4. Faruqi & Faruqi is investigating claims for investors losing money. 5. Investors are encouraged to discuss legal options regarding losses.
The significant decline in share price indicates severe investor negativity. Historical instances show declines often lead to prolonged negative sentiment.
The investigation and drastic price drop signal serious concerns for investors. Legal ramifications from lost trust can hinder recovery.
The immediate reaction to trial results is direct; however, long-term effects depend on recovery strategies. Previous failed trials also led to long-term reputational harm.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Alto Neuroscience To Contact Him Directly To Discuss Their Options
If you suffered significant losses in Alto Neuroscience stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE:ANRO).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. That press release stated, in relevant part, that "ALTO-100 in patients with [MDD] did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo."
On this news, Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024. Analysts were quick to comment on the Company's announcement. For example, on October 22, 2024, Jeffries cut its price target for Alto to $17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry.
To learn more about the Alto Neuroscience investigation, go to www.faruqilaw.com/ANRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909437728/en/
Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)